StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
RLMDRELMADA THERAPEUTICS, INC.
stockpulse.co.kr
Nasdaq
$3.27▲ 0.31%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $343.0MShares out 100M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

7
  • 9.11Pre-market26.09.11 20:30
    4Ownership#●●●#●●●

    RELMADA THERAPEUTICS, INC.

    Maged Shenouda, an insider at Relmada Therapeutics, Inc., reported a change in beneficial ownership of securities effective September 9, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more

    $3.27+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.11Pre-market26.09.11 20:30
    4Ownership

    RELMADA THERAPEUTICS, INC.

    Sergio Traversa, a director at Relmada Therapeutics, Inc., filed a Form 4 on September 11, 2026, regarding a change in beneficial ownership of securities as of September 9, 2026. This filing serves as an official report to the SEC concerning the insider's stock holdings.…more

    $3.27+0.31%vs prev close
    View filingShare
  • 9.8Pre-market26.09.08 21:00
    8-KKey event

    RELMADA THERAPEUTICS, INC.

    Dr. Raj S. Pruthi, the Chief Medical Officer of Urology at Relmada Therapeutics, Inc., ended his employment with the company on September 3, 2026. This leadership change marks a departure in the company's medical executive team.…more

    $3.27+0.31%vs prev close
    View filingShare

6 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.1Pre-market26.09.01 21:00
    #●●●#●●●

    Relmada Therapeutics to Participate in Wells Fargo Healthcare Conference…more

    Relmada Therapeutics announced that its senior management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference. This is a standard investor relations event and does not provide immediate material impact on the stock.…more

    $3.27+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 7.28Pre-market26.07.28 21:30

    ●●●●●●●● ●●●●● ●●●●●●

    렐마다 테라퓨틱스가 비뇨기 종양 분야 전문가인 비핀 달미아를 최고사업책임자(CBO)로 영입했습니다. 이번 경영진 인사를 통해 회사의 사업 전략 강화와 파이프라인 개발 속도가 빨라질 것으로 기대됩니다.…more

    $3.27+0.31%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →